Added to YB: 2026-04-15
Pitch date: 2026-04-03
CRMD [bullish]
CorMedix Inc.
+3.11%
current return
Author Info
Company Info
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
Market Cap
$572.3M
Pitch Price
$7.08
Price Target
40.59 (+456%)
Dividend
N/A
EV/EBITDA
3.21
P/E
3.55
EV/Sales
1.80
Sector
Pharmaceuticals
Category
growth
CorMedix's (NASDAQ:CRMD) Climb
CRMD: Early-commercial biopharma w/ DefenCath (catheter lock solution reducing CRBSIs ~70% in hemodialysis). Acquired Melinta Aug 2025, adding anti-infectives. Expanding DefenCath to TPN ($500M-$750M addressable) & pediatrics. NCE exclusivity to 2033, patents to 2042. Trading below intrinsic value despite structural dialysis market growth (5-7% CAGR). 3yr PT $25.43 (15x FY28 NI $143.51M), 5yr PT $40.59 (15x FY30 NI $229.01M). Risks: revenue concentration, reimbursement dependency (TDAPA expiring), supply chain. Strong clinical data (70% infection reduction) & cost-effectiveness support adoption. Proven mgmt, 500+ institutions. Buy.
Read full article (12 min)